Compton Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,094
| Closed | -$812K | – | 9 |
|
|
2023
Q1 | $812K | Sell |
5,094
-13,100
| -72% | -$2M | 1.75% | 15 |
|
|
2022
Q4 | $2.94M | Sell |
18,194
-1,600
| -8% | -$245K | 2.12% | 12 |
|
|
2022
Q3 | $2.66M | Sell |
19,794
-1,381
| -7% | -$198K | 1.78% | 13 |
|
|
2022
Q2 | $3.24M | Sell |
21,175
-13,638
| -39% | -$2.08M | 1.79% | 12 |
|
|
2022
Q1 | $5.64M | Sell |
34,813
-630
| -2% | -$91.5K | 1.58% | 11 |
|
|
2021
Q4 | $4.8M | Sell |
35,443
-985
| -3% | -$116K | 1.25% | 16 |
|
|
2021
Q3 | $3.93M | Buy |
36,428
+596
| +2% | +$68.1K | 1.15% | 19 |
|
|
2021
Q2 | $4.04M | Sell |
35,832
-200
| -0.6% | -$22.5K | 1.19% | 20 |
|
|
2021
Q1 | $3.9M | Sell |
36,032
-500
| -1% | -$53.5K | 1.22% | 21 |
|
|
2020
Q4 | $3.91M | Buy |
36,532
+757
| +2% | +$72.7K | 1.32% | 19 |
|
|
2020
Q3 | $3.13M | Sell |
35,775
-274
| -0.8% | -$25.8K | 1.2% | 22 |
|
|
2020
Q2 | $3.54M | Buy |
36,049
+1,653
| +5% | +$146K | 1.48% | 19 |
|
|
2020
Q1 | $2.62M | Buy |
34,396
+1,295
| +4% | +$110K | 1.29% | 23 |
|
|
2019
Q4 | $2.93M | Sell |
33,101
-1,950
| -6% | -$162K | 1.14% | 27 |
|
|
2019
Q3 | $2.65M | Buy |
35,051
+2,860
| +9% | +$196K | 1.11% | 28 |
|
|
2019
Q2 | $2.34M | Buy |
32,191
+6,610
| +26% | +$520K | 0.99% | 33 |
|
|
2019
Q1 | $2.06M | Sell |
25,581
-200
| -0.8% | -$16.4K | 0.9% | 40 |
|
|
2018
Q4 | $2.38M | Sell |
25,781
-2,320
| -8% | -$204K | 1.13% | 25 |
|
|
2018
Q3 | $2.66M | Buy |
28,101
+375
| +1% | +$35.6K | 1.05% | 29 |
|
|
2018
Q2 | $2.57M | Buy |
27,726
+172
| +0.6% | +$16.8K | 1.09% | 27 |
|
|
2018
Q1 | $2.61M | Buy |
27,554
+455
| +2% | +$50K | 1.11% | 26 |
|
|
2017
Q4 | $2.62M | Buy |
27,099
+95
| +0.4% | +$8.95K | 1.12% | 25 |
|
|
2017
Q3 | $2.4M | Sell |
27,004
-961
| -3% | -$73.2K | 1.08% | 29 |
|
|
2017
Q2 | $2.03M | Buy |
27,965
+825
| +3% | +$55.5K | 0.92% | 36 |
|
|
2017
Q1 | $1.77M | Sell |
27,140
-800
| -3% | -$50.3K | 0.87% | 38 |
|
|
2016
Q4 | $1.75M | Sell |
27,940
-28,040
| -50% | -$1.71M | 0.92% | 37 |
|
|
2016
Q3 | $3.5M | Buy |
55,980
+27,840
| +99% | +$1.8M | 0.97% | 32 |
|
|
2016
Q2 | $1.74M | Sell |
28,140
-1,300
| -4% | -$79.2K | 0.97% | 33 |
|
|
2016
Q1 | $1.68M | Sell |
29,440
-350
| -1% | -$19.5K | 0.94% | 31 |
|
|
2015
Q4 | $1.76M | Sell |
29,790
-350
| -1% | -$20.2K | 1% | 31 |
|
|
2015
Q3 | $1.64M | Sell |
30,140
-4,430
| -13% | -$288K | 0.59% | 30 |
|
|
2015
Q2 | $2.32M | Buy |
34,570
+400
| +1% | +$26.1K | 1.28% | 21 |
|
|
2015
Q1 | $2M | Sell |
34,170
-15
| -0% | -$906 | 1.11% | 28 |
|
|
2014
Q4 | $2.24M | Sell |
34,185
-2,150
| -6% | -$136K | 1.22% | 26 |
|
|
2014
Q3 | $2.1M | Buy |
36,335
+40
| +0.1% | +$2.22K | 1.14% | 27 |
|
|
2014
Q2 | $2.05M | Buy |
36,295
+867
| +2% | +$45.5K | 1.1% | 27 |
|
|
2014
Q1 | $1.82M | Hold |
35,428
| – | – | 1.05% | 29 |
|
|
2013
Q4 | $1.87M | Buy |
35,428
+1,377
| +4% | +$67.7K | 1.07% | 31 |
|
|
2013
Q3 | $1.52M | Buy |
34,051
+125
| +0.4% | +$5.54K | 0.93% | 33 |
|
|
2013
Q2 | $1.4M | Buy |
+33,926
| New | +$1.48M | 0.87% | 35 |
|
Other funds holding ABBV
Compton Capital Management's ABBV Position: Q2 2023 in Review
Compton Capital Management sold out of AbbVie (ABBV) in Q2 2023, closing a stake of 5,094 shares — an estimated $812K sold.
Compton Capital Management first reported a position in ABBV in Q2 2013 and held it in 40 quarters. The position peaked at $5.64M in Q1 2022. 3,076 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.
- Compton Capital Management reported no remaining AbbVie position as of Q2 2023 after selling out during the quarter.
- Compton Capital Management sold 5,094 AbbVie shares in Q2 2023, an estimated $812K.
- Compton Capital Management first reported a position in AbbVie in Q2 2013 and held it in 40 quarters.
- Compton Capital Management's AbbVie position peaked at $5.64M in Q1 2022.
- 3,076 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.
Based on Compton Capital Management's 13F filing for Q2 2023, filed 9 Aug 2023.